A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts
The goal of this clinical research study is to learn about the safety of giving 1 of 3 different dose levels of Thrombosomes to hospitalized patients with low platelet count who are actively bleeding or at risk of active bleeding. Researchers also want to learn if Thrombosomes affects bleeding and blood clotting.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Thrombosomes
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Cellphire, Inc.
IRB Review and Approval Date: 09/05/2018
Recruitment Status: Open
Projected Accrual: 24
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: